Coronavirus vaccine sponsors may be stuck with the US Food and Drug Administration’s call for placebo-controlled follow up of COVID-19 vaccines after they receive emergency use authorization. The agency's Vaccines and Related Biological Products Advisory Committee reaffirmed the need for such data to support a full biologics license application during its 22 October meeting.
Yet neither the FDA nor the advisory committee offered companies much advice on how to achieve this outcome, which they...





